Levels of evidence | |
1++ | High-quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias |
1+ | Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias |
1− | Meta-analyses, systematic reviews, or RCTs with a high risk of bias |
2++ | High-quality systematic reviews of case–control or cohort studies |
High-quality case–control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal | |
2+ | Well-conducted case–control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal |
2− | Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal |
3 | Non-analytical studies (eg, case reports, case series) |
4 | Expert opinion |
Grades of recommendations | |
A | At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or |
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results | |
B | A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or |
Extrapolated evidence from studies rated as 1++ or 1+ | |
C | A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or |
Extrapolated evidence from studies rated as 2++ | |
D | Evidence level 3 or 4; or |
Extrapolated evidence from studies rated as 2+ |
Good practice points | |
√ | Recommended best practice based on the clinical experience of the guideline development group |
Note: the grade of recommendation relates to the strength of the evidence on which the recommendation is based. It does not reflect the clinical importance of the recommendation.